Advertorial Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders HO Mar 31, 2026 Mar 31, 2026 Updated 1 hr ago Facebook Twitter WhatsApp SMS Email Print Copy article link Save Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company) HO As featured on Lilly Employer Connect platform launches with over fifteen independent program administrators offering tailored obesity coverage options to expand access to patients Zepbound® (tirzepatide) KwikPen® for single-patient use available from Lilly at $449 across … Lilly's EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitis In the Phase 3 ADorable-1 study, 63% of patients achieved meaningful skin improvement (EASI-… Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes For the primary endpoint, retatrutide lowered A1C by an average of 1.7% to 2.0% across doses… Facebook Twitter WhatsApp SMS Email Print Copy article link Save Sections AutomotiveBridalBusiness And CareersCommunity CaresEducationEspanolFamily LivingFashion, Beauty & FitnessFood, Recipes & EntertainingGift IdeasGreen LivingHealth & WellnessHome DecoratingHome ImprovementHot TopicsHow ToKitchen, Bed & BathLawn & GardenMoney & FinancePetsPress ReleasesReal EstateSeasonalSenior LivingSportsTech Talk & InnovationTravel Trending Now Delaware Officially Sanctions Girls Wrestling as Championship Sport Highlights: Worcester Prep Explodes In Fourth Quarter For Road Victory Kent Island lacrosse defeat Stephen Decatur 9-7 in rematch of 2025 state championship. Highlights: Stephen Decatur Rallies Over Parkside, 4-3 Decatur shuts out Cape Henlopen 4-0 to improve to 5-1 on the year
Lilly Employer Connect platform launches with over fifteen independent program administrators offering tailored obesity coverage options to expand access to patients Zepbound® (tirzepatide) KwikPen® for single-patient use available from Lilly at $449 across …
Lilly's EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitis In the Phase 3 ADorable-1 study, 63% of patients achieved meaningful skin improvement (EASI-…
Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes For the primary endpoint, retatrutide lowered A1C by an average of 1.7% to 2.0% across doses…
